Aethlon Medical to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Aethlon Medical, Inc. (Nasdaq: AEMD) will present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference from September 13-15, 2021. CEO Charles J. Fisher will offer an overview on September 13 at 7:00 AM EDT, available on-demand for 90 days. Aethlon’s Hemopurifier, a clinical-stage device for treating cancer and viral infections, holds FDA's Breakthrough Device designation. The company also operates Exosome Sciences, focused on exosomal biomarkers for cancer and neurological diseases.
- None.
- None.
SAN DIEGO, Sept. 7, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced that it will be presenting at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference. The conference is being held virtually from September 13-15, 2021.
Charles J. Fisher, M.D., Chief Executive Officer, will present an overview of Aethlon Medical the conference. The presentation will be available on-demand beginning Monday, September 13 at 7:00 AM EDT at the link below and will be archived for 90 days. It will also be available on the Aethlon website. In addition to the overview presentation, Dr. Fisher will be hosting virtual one-on-one meetings at the conference on Monday, September 13.
Event: H.C. Wainwright 23rd Annual Global Investment Conference (Virtual Conference)
Date: September 13, 2021
Time: 7:00 AM EDT
Location: Virtual Conference
Company Webcasting Link: https://journey.ct.events/view/11f097cf-439f-49c7-9a8c-10f0dfa0fe5e
About Aethlon and the Hemopurifier®
Aethlon is focused on addressing unmet needs in global health. The Aethlon Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In cancer, the Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression.
The Hemopurifier is an FDA designated "Breakthrough Device" related to the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. Under an Investigational Device Exemption (IDE) application, in October 2019, the FDA approved an Early Feasibility Study (EFS), which is the device equivalent of a Phase 1 clinical trial for a drug or biologic, in a single center, open label trial in 10 to 12 subjects. The study is evaluating the HEMOPURIFIER® for reducing cancer-associated exosomes prior to the administration of standard-of-care pembrolizumab (KEYTRUDA®), which is a first-line therapy for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. The EFS is being conducted at the University of Pittsburgh Medical Center Hillman Cancer Center.
The Hemopurifier also holds a Breakthrough Device designation related to life-threatening viruses that are not addressed with approved therapies. In June 2020, the FDA approved an amendment to the Company's existing open IDE for the Hemopurifier in life threatening viral infections to allow for the treatment of patients with SARS-CoV-2/COVID-19 infection. This will allow for up to 40 of these patients to be treated under a new Early Feasibility Study protocol at up to 20 clinical sites in the U.S.
Aethlon also owns
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to enroll patients in and successfully complete trials in the Early Feasibility Studies in head and neck cancer and in COVID-19 patients, the Company's ability to successfully treat patients under any Emergency Use pathway, the Company's ability to successfully complete development of its Hemopurifier, the Company's ability to raise additional funds, and other potential risks. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2021, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.
Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-459-7800 x3300
Jfrakes@aethlonmedical.com
Media Contact:
Tony Russo, Ph.D.
Russo Partners, LLC
tony.russo@russopartnersllc.com
212-845-4251
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
212-966-3650
View original content:https://www.prnewswire.com/news-releases/aethlon-medical-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-301370027.html
SOURCE Aethlon Medical, Inc.
FAQ
When will Aethlon Medical present at the H.C. Wainwright 23rd Annual Global Investment Conference?
What is the focus of Aethlon Medical's presentation at the conference?
How long will Aethlon Medical's presentation be available for viewing?
What is the significance of the Hemopurifier device developed by Aethlon Medical?
What are the recent studies related to the Hemopurifier?
